The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Personalizing CLL therapy in the frontline
Parag Jasani, FRCPath, MBBS, MRCP, Royal Free London NHS Foundation Trust, London, UK, explores personalized approaches to treating patients with chronic lymphocytic leukemia (CLL) in the frontline setting. Personalization involves tailoring combinations of anti-CD20 antibodies, BCL2 inhibitors, and BTK inhibitors based on individual factors such as underlying comorbidities and patient preferences. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Abbvie, Astra Zeneca.
